Oppenheimer & Co’s Encompass Health EHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.61M Buy
89,062
+7,300
+9% +$749K 0.1% 208
2025
Q4
$8.68M Sell
81,762
-9,735
-11% -$1.13M 0.12% 182
2025
Q3
$11.6M Sell
91,497
-6,917
-7% -$823K 0.14% 157
2025
Q2
$12.1M Sell
98,414
-2,225
-2% -$254K 0.16% 141
2025
Q1
$10.2M Sell
100,639
-131
-0.1% -$12.8K 0.15% 143
2024
Q4
$9.31M Sell
100,770
-4,241
-4% -$416K 0.14% 150
2024
Q3
$10.1M Sell
105,011
-12,240
-10% -$1.1M 0.15% 145
2024
Q2
$10.1M Sell
117,251
-950
-0.8% -$79.7K 0.16% 130
2024
Q1
$9.76M Buy
118,201
+6,280
+6% +$460K 0.16% 138
2023
Q4
$7.47M Sell
111,921
-1,580
-1% -$102K 0.14% 178
2023
Q3
$7.62M Buy
113,501
+10,958
+11% +$754K 0.16% 148
2023
Q2
$6.94M Sell
102,543
-21,890
-18% -$1.37M 0.14% 168
2023
Q1
$6.73M Sell
124,433
-11,072
-8% -$644K 0.14% 168
2022
Q4
$8.1M Sell
135,505
-5,275
-4% -$287K 0.18% 128
2022
Q3
$6.37M Sell
140,780
-36,114
-20% -$1.81M 0.15% 159
2022
Q2
$7.89M Sell
176,894
-8,045
-4% -$413K 0.17% 132
2022
Q1
$10.5M Sell
184,939
-9,785
-5% -$511K 0.19% 113
2021
Q4
$10.1M Sell
194,724
-1,124
-0.6% -$58K 0.18% 117
2021
Q3
$11.7M Buy
195,848
+31
+0% +$1.95K 0.22% 95
2021
Q2
$12.2M Buy
195,817
+2,791
+1% +$186K 0.22% 100
2021
Q1
$12.6M Sell
193,026
-59,806
-24% -$3.9M 0.25% 83
2020
Q4
$16.6M Buy
252,832
+2,451
+1% +$144K 0.35% 60
2020
Q3
$12.9M Sell
250,381
-20,929
-8% -$1.07M 0.32% 63
2020
Q2
$13.4M Sell
271,310
-4,980
-2% -$269K 0.35% 60
2020
Q1
$14.1M Sell
276,290
-4,761
-2% -$275K 0.43% 50
2019
Q4
$15.5M Sell
281,051
-7,165
-2% -$389K 0.38% 56
2019
Q3
$14.5M Sell
288,216
-3,545
-1% -$178K 0.4% 53
2019
Q2
$14.7M Buy
291,761
+1,402
+0.5% +$68K 0.4% 53
2019
Q1
$13.5M Sell
290,359
-202
-0.1% -$10.2K 0.36% 60
2018
Q4
$14.3M Buy
290,561
+3,771
+1% +$214K 0.45% 48
2018
Q3
$17.8M Sell
286,790
-6,285
-2% -$382K 0.45% 46
2018
Q2
$15.8M Sell
293,075
-33,380
-10% -$1.67M 0.43% 48
2018
Q1
$14.8M Sell
326,455
-4,526
-1% -$194K 0.38% 56
2017
Q4
$13M Buy
330,981
+1,789
+0.5% +$68K 0.33% 63
2017
Q3
$12.1M Buy
329,192
+10,936
+3% +$390K 0.32% 65
2017
Q2
$12.3M Sell
318,256
-87,541
-22% -$3.21M 0.34% 62
2017
Q1
$13.8M Sell
405,797
-23,016
-5% -$756K 0.39% 54
2016
Q4
$14.1M Sell
428,813
-18,930
-4% -$614K 0.41% 53
2016
Q3
$14.5M Sell
447,743
-755
-0.2% -$24.5K 0.42% 57
2016
Q2
$13.9M Sell
448,498
-11,017
-2% -$345K 0.41% 53
2016
Q1
$13.8M Sell
459,515
-2,322
-0.5% -$64.1K 0.42% 53
2015
Q4
$12.8M Buy
461,837
+2,414
+0.5% +$68.7K 0.38% 57
2015
Q3
$14M Buy
459,423
+84,931
+23% +$2.96M 0.43% 44
2015
Q2
$13.7M Sell
374,492
-33,579
-8% -$1.2M 0.38% 54
2015
Q1
$14.4M Sell
408,071
-29,202
-7% -$999K 0.39% 54
2014
Q4
$13.4M Buy
437,273
+43,281
+11% +$1.35M 0.38% 50
2014
Q3
$11.6M Sell
393,992
-62,912
-14% -$1.92M 0.34% 55
2014
Q2
$13M Sell
456,904
-32,054
-7% -$894K 0.39% 47
2014
Q1
$14M Sell
488,958
-2,011
-0.4% -$52.3K 0.42% 43
2013
Q4
$13M Buy
490,969
+1,885
+0.4% +$52.4K 0.42% 44
2013
Q3
$13.4M Buy
489,084
+13,589
+3% +$349K 0.47% 38
2013
Q2
$10.9M Buy
+475,495
New +$10.7M 0.42% 42

Other funds holding EHC

Oppenheimer & Co's EHC Position: Q1 2026 in Review

Oppenheimer & Co increased its Encompass Health (EHC) stake by 8.9% in Q1 2026, buying an estimated $749K and bringing the position to 89,062 shares worth $8.61M. The position accounts for 0.1% of the portfolio, ranked #208.

Oppenheimer & Co first reported a position in EHC in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.8M in Q3 2018. 578 funds tracked by Wall St. Rank hold EHC as of Q1 2026.

  • Oppenheimer & Co held 89,062 shares of Encompass Health worth $8.61M as of Q1 2026.
  • Oppenheimer & Co bought 7,300 Encompass Health shares in Q1 2026, an estimated $749K.
  • Encompass Health made up 0.1% of Oppenheimer & Co's portfolio in Q1 2026, its #208 holding.
  • Oppenheimer & Co first reported a position in Encompass Health in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Encompass Health position peaked at $17.8M in Q3 2018.
  • 578 funds tracked by Wall St. Rank held Encompass Health as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.